News | May 17, 2024
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
EBITDA before special items falls 1.3 percent to € 4.41 billion
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Investing in Malaysia's largest clinic operator to expand the healthcare business
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
Subscribe To Our Newsletter & Stay Updated
